May 2024- BD announced that Rima Alameddine has been named worldwide president of the BD Peripheral Intervention business unit.
In this role, Alameddine will be responsible for driving the global strategic, operational, quality and commercial excellence of the Peripheral Intervention business unit. She will report to Rick Byrd, Executive Vice President & President of the BD Interventional Segment.
Click here to join our WhatsApp channel
“With more than 25 years of health care industry experience, Rima is a passionate leader with a track record of strong execution,” Byrd said. “The combination of Rima’s leadership and a vibrant pipeline of innovations put BD Peripheral Intervention in a strong position to accelerate growth for the business and serve patients across a variety of peripheral vascular and oncology applications.”
Alameddine joins BD Peripheral Intervention from BD Urology and Critical Care, where she has served as worldwide president since October 2021. She joined BD in 2015 as the vice president and general manager for C. R. Bard in Latin America, and in 2019, she was appointed vice president and general manager for the Oncology platform within BD Peripheral Intervention, where she focused on global expansion, driving new product development and building a robust funnel of tuck-in acquisition opportunities. Prior to BD, Alameddine spent 11 years at GE Healthcare in various leadership positions, including chief marketing officer for Latin America.
Alameddine earned her Doctorate in Pharmacy and Biochemistry from the University of Sao Paulo and an extended degree in Marketing from ESPM (Superior School of Propaganda and Marketing) in Brazil.
